Advancing The Next Paradigm Shift in the Treatment of Onychomycosis

FDA approval of systemic antifungals in the nineties represented the first paradigm shift in the treatment of onychomycosis. However, the topical products that followed failed to match the effectiveness of orals because of their inability to adequately penetrate the nail plate and reach nail bed infection sites at therapeutic levels to kill causative fungi. Hallux Inc. is pioneering a new pharmacologic approach with Hallux Subungual Gel (HSG), a terbinafine dosage form applied directly onto the mycotic nail bed by physicians in-clinic. This atraumatic route to the nail bed is made possible by allowable subungual space, tiny pockets and channels under detached nail created by pre-existing onycholysis. HSG has completed a  multi-site, Phase 2a efficacy, safety, and pharmacokinetics study evaluating once-monthly and once bi-monthly applications over 44 weeks. Encouraging data has led to the design of a well-controlled Phase 2b, which will commence in the 4th quarter of 2026. Up to 15 clinical sites across the country will participate.

The risk of becoming infected with onychomycosis increases with age. Over eight million patients see physicians each year to remedy their unsightly and often painful fungal nails. The most effective prescription agent remains oral terbinafine (Lamisil®), dosed every day for three months. Topical antifungals are preferred due to the absence of systemic side effects. However, only a handful of agents are FDA approved, and each requires self-application every night for 12 months or more. Sadly, none work very well and most patients quit using them after a few months.

Hallux hopes to fill this gap with clinically proven, and FDA approved HSG, under development to be a safe, highly effective, and affordable treatment alternative administered by a local podiatrist or dermatologist at the point-of-care. The Phase 2b trial will evaluate once-monthly dosing of HSG up to 48 months in a mild-to-moderately severe patient population, including those with conditions further compromised by the disease subytype dermatophytoma.